The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.

With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate NVX‑CoV2373.

Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).

As the United States accelerates the search for a coronavirus vaccine, tensions have erupted between government scientists and Moderna Inc., one of the leading developers, Reuters has learned.

COVID-19 vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said.

U.S. National Institutes of Health Director Dr. Francis Collins said he was optimistic that the Trump administration’s vaccine-acceleration program “Operation Warp Speed” will generate a safe and effective vaccine for COVID-19 by year end.

One month after Vaxart announced the selection of its lead vaccine candidate for COVID-19, the Bay Area-based company was selected to participate in the U.S. government’s Operation Warp Speed program.

Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration narrowed that list to five potential treatments for the prevention of the novel coronavirus.

CDMO Emergent BioSolutions signed a public-private partnership for the U.S. government’s initiative to accelerate production of a vaccine against COVID-19.

The U.S. government entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine.